Alrighty. Good afternoon, everyone. I hope day two of our London Healthcare Conference is going well. Again, thrilled to see the turnout, and I hope everyone's meetings are going as well as we hope. My name's Akash Tewari. I lead our Pharma and Biotech Research efforts within the firm. I have the pleasure of hosting the Gilead management team. Dan and Andy, it's really such a pleasure to have you. Why don't I hand it off to you for some opening remarks, and then we'll get started?
Sure. Thank you very much for having us here. Delighted to be here with all of you. Andy and I are here representing the team, I think, that has done some pretty extraordinary work over the past many years, and really, I think, a strong time in the evolution of the Gilead story, in that we have, I think, very much strengthened the HIV business overall at Gilead over the past many years, and added two substantial new areas of focus for us. Obviously, one is oncology and one is inflammation. I think we're in a very strong position. We're coming off of the strongest growth we've had in more than a decade in the third quarter, driven really across the therapeutic areas.
Strong growth in HIV, strong growth in oncology, in particular in our TRODELVY business, and then LIVDELZI on the PBC side, the beginning of our inflammation approach. We feel really good about where we're at. I would say that we also feel we're at the very beginning of unpacking the diversification story, the diversification story within HIV and the diversification story outside of HIV. We're firmly committed to just a continual series of innovations between now and really the next. The only major patent cliff we have right now is 2036 in BIKTARVY, and we feel we're in a very good position to strengthen and diversify our HIV treatment business well before the 2036 patent. That, combined with the other two therapeutic areas, puts us in a very strong position, and we're very committed to running a very operationally efficient business as well.
We expect good, strong growth on the top and bottom line moving forward. Look forward to your questions.
I really appreciate it. I mean, I would agree, you have two foundational assets, oncology and then in I&I with the oral ENTYVIO. Tubulis, that's a platform you can really build on. Let's start with I&I. You had really interesting data. It certainly looks like an active molecule. It can rival what we've seen with the biologics. So much, I feel like, of what your team goes into markets, it's not just the asset, but it's really the strategy, and how you see it playing out that might be different than others. You have an oral ENTYVIO. You also recently in-licensed an oral IL-23. So, two oral assets. What do you think the market misunderstands when you can deliver oral biologic efficacy that is obvious to your team right now?
Can you talk a bit about what your plan of attack is for mild patients, right? Going up the disease category, so not just for late-stage patients, but with an oral therapy. Could we see your drug actually expand the market and grow it in a way that maybe we don't appreciate right now?
Sure. Maybe just to give a little context, and I invite Andy in to add, obviously, on this. When we started this journey about eight years ago, and we decided to expand into oncology and inflammation, it was really around two key strengths we had at the company at the time. One was immunology, biological expertise, but the other one at the time was small molecules. Since then, by the way, we've expanded. We're the world leaders in cell therapy. We have a very strong biologic base, and the combination of biologics and small molecules gives us a unique position in the ADC market as well.
When we started this, back to your question, it was really around how do we leverage our small molecule chemistry to approach known targets in inflammation, but with unique molecules that could not only be effective as single agents, but very importantly, because we know we're a new entrant to the space, the potential to combine multiple agents in inflammation, which has been something that has escaped much of the science of this area. We all know we've been dealing with kind of efficacy ceilings in many disease states across inflammation, and that's largely because of a single-agent tolerance level. Being able to combine agents, we always thought would help get us to a different level of efficacy at the end of the day. So, it wasn't just about taking an injectable and turning it into a pill.
It was about taking a target and allowing it to be combinable to get through an efficacy barrier. Now, what we've seen so far, and it's early days, but the two data sets that are probably out there in our work, phase II, are the IRAK4 and the alpha-4-beta-7. To your question around alpha-4-beta-7, we think it's a very attractive data set for a phase II. It looks like potentially IV-level efficacy or injectable-level efficacy in a pill with a very good tolerability profile. We will pursue that in monotherapy as we approach an alternative for patients with UC and IBD, but we'll also be pursuing it in parallel in combination. It could go with a variety of different mechanisms.
We do think IL-23 is a particularly good mechanism, but it's not the only mechanism, which is why we in-license a product in early IL-23 that we think is very interesting. I don't want you to believe that that's the only combination we could imagine alpha-4-beta-7 working with. We could look at other IL-23s. We could look at other mechanisms moving forward. To your question on kind of moderate disease moving forward, I think first of all, the tolerability profile allows one to think earlier in more moderate stage diseases, because benefit-risk, obviously, in this population, the milder you get, the more you need a better tolerability profile, which we think both, frankly, the alpha-4-beta-7 and potentially the IL-23, either as a monotherapy or in combination, have the type of profiles to get into that earlier stage moderate patient. If you want to add on.
Yeah, I mean, first of all, Akash, thanks for having us and thanks for the question. Look, I don't think there's a lot. When you say, what does the market not understand that we understand? I think it's the. People knew that we were building an inflammation franchise, but they just weren't following it as closely because we didn't yet have phase II data. In the last couple of weeks, you now have the oral alpha-4-beta-7 data. You have the IRAK4 small molecule. We also have an IRAK4 degrader, but IRAK4 small molecule data that was at ACR and cutaneous lupus this weekend. That's very exciting. Small dataset, phase kind of II-A dataset, but very exciting. We're going to have our gamgertamig, which is our B cell depleter. This is a BCMAx CD3 T cell depleter. That data will be at ASH. That's in partnership with our partner, Lakefront Biotherapeutics.
There's four or five other programs around it. I think the world knew that we were building this, but they're just now kind of paying attention as we're developing more data. Again, we have a number of programs across Kite that are also working in autoimmune with both anito-cel as well as a CD19/ CD20 bispecific. There's just a lot happening here, and the datasets are just starting to come out, which is then giving people a glimpse. I think to Dan's point, the last thing I'll say is on monotherapy, or on the mild disease, both the oral alpha-4-beta-7 as a monotherapy may be able to kind of look at more mild disease. Then part of what we really liked about this IL-23 peptide that we're acquiring from a company in China is that it's very potent.
It has potential for once-monthly oral dosing. When you think of that as a monotherapy, whether it's in dermatological conditions or in UC, it could be something that's used across the spectrum, including potentially in mild disease.
Understood. Dan, you said something pretty provocative there, because you said, look, we can combine with the oral IL-23 we just got, but there could be other IL-23s we're looking at. Because again, I think a lot of it is, I think to Andy's point, it's we understand the targets. We know these are big markets. It's like, well, when are we going to start getting revenues from Gilead, right? I think that's really where there's the desire. I can't help but think there are other companies that have assets already on the market that also have really a dominant presence in I&I, because you have to build out that sales force as well, where I feel like your team could leverage.
Can you expand a bit more about with the oral ENTYVIO, how aggressively are you looking at on the market, or near to market oral combination options outside of the IL-23 that you recently in-licensed?
Yeah, I mean, just to make sure we frame this. Look, I think the growth story for Gilead is around HIV and around oncology in the 2020s. Our inflammation story is really around a 2030 growth story, which is important because we want to make sure we have continual innovation 2030 into the 2040s and beyond. Having said that, probably gamgertamig, which Andy mentioned, is our first potential launch, that B cell depleter, because it's in more of an orphan disease, and so the clinical trials can go with a little bit more expeditious nature, and we could see that potentially on the earlier 2030 side. But to your point, I mean, I think when you —look, we've always been an outside-in company. This is true in our history in HIV and in hepatitis. Of course, we'll do things as Gilead-owned combinations, but we have no issue.
In fact, the patients are really what we are focused on. The question is if there are attractive opportunities, to your point, later stage or on-market assets that could be combinable with alpha-4-beta-7 or other things within our portfolio, we will continue to pursue that. Obviously, you have to strike the right agreements with individuals that may have those mechanisms. I would say that there is no reason why you cannot consider multiple combinations here, either co-packaged or eventually you could. We think a lot about co-formulation as well with our agents for the ease of patients, and that is something that our chemists are particularly well-suited to kind of consider.
Understood. Maybe just lastly on this point, because there is a little street debate of, is the IL-23 that your team got something that you could pursue a co-formulation strategy? I know we do not have perfect information, but I cannot think that you would in-license an asset that you wouldn't be co-formulation friendly with your existing programs. Is that general observation fair here?
The general observation is fair. It is too early to comment exactly. But one of the reasons, to Andy's point, the potency of this IL-23 that we brought in, because you are dealing with active ingredient size, and how much can you fit into a pill at the end of the day. These are really important points. So the potency of this, given the fact that it has a potential half-life that could be considered once a month in some indications, allows you to imagine a very small level of ingredient that would go into a once-a-day pill. So those are things that we think thoughtfully about, but we are also driven by science and the ability to see how co-formulation can work beyond that.
Right. I think maybe a transition a bit to oncology and Tubulis. I know I came from ESMO, very, very impressive Rina-S data in ovarian cancer, and there is just no doubt about that. That is going to be standard of care changing. But I do feel like, look, if it was Rina-S, it would have been the CDH6, it would have. I mean, there are five different assets in ovarian cancer that are not showing a biomarker, that are having a higher than 50% response rate. So, if it was not Genmab, it was going to be someone else, right? That was not really the bet that you made with Tubulis. It was, A, the efficacy, but B, it was really the combinability, right?
Can you give us a view, knowing what you know now on the Rina-S data set and the bet you made with Tubulis, are you still confident that you could have a differentiated profile here in ovarian cancer?
I mean, the answer is yes. I mean, the attractive thing about Tubulis is it wasn't just about any one particular disease state or one particular, frankly, linker or payload. It was the totality of what Tubulis brings, I think, to Gilead, and we're very excited. We've got colleagues now in Munich that will be stationed there as a center of excellence, working with our colleagues back in Foster City. The lead approach is on NaPi2b, as you said, and in ovarian cancer, but not only ovarian cancer, by the way. Endometrial, lung cancer, other indications can be said with NaPi2b. There's other targets, 5T4, that are potentially entering the clinic soon, and there's other payloads.
But the thing we really liked to your combinability issue, maybe somewhat analogous to what we spoke about in the small molecule alpha-4-beta-7, is in this particular case, the linker is very, very tight. In other words, while TRODELVY is a very attractive and effective medicine, particularly in breast cancer, that's a looser linker, and you're getting a bystander effect. And that it's difficult to combine, to double down on toxicities when you have a bystander effect for a chemo payload. But where the linker was really tight, and we believe it is, and of course, the lead indication is platinum-resistant ovarian cancer. But we also have programs now in platinum-sensitive ovarian cancer.
And to your point, we think there's, you know, we like the data we're seeing on the ability to think about NaPi2b combined with either a chemo or another agent to get a larger effect size in ovarian cancer. And that's not just, by the way, for that. I think that same linker will play through to other disease states for both potential monotherapy and combination therapy. But of all the ADCs we've seen, and we've seen a lot since we acquired Immunomedics about seven or eight years ago.
We think that this platform has the best ability on a tolerability basis to think about combining with other agents in all forms of cancer and different payloads.
Understood. Just a bit on that. It does seem like in oncology, everyone has assets. It is really also speed of execution. I thought it was very pragmatic of your team. You have TRODELVY, but you looked externally for a PD-1 matchup. I know your team may be looking for an internal one too, but pumitamig is out there. It should get on the market relatively soon. They know what their kind of dose is, and that is a strategic advantage in terms of moving fast. As you think about Tubulis, A, how certain is your team that you have a phase III-ready dose in ovarian cancer, and is there any catalysts or data update in 2027 that will help the street feel comfortable?
Number two, kind of the strategy that you took in TNBC, could we also see that in ovarian, where, again, you look externally for combination approaches to really get a best-in-class regimen for ovarian?
We feel good about the dose going into ovarian. I am not sure exactly when next year we will share more data, but I am sure we will. On the second point, sorry, I forgot the second point.
Where you looked at pumitamig.
Oh, yeah, right. The combination with TRODELVY and the BioNTech compound in breast cancer, would we look at something like that for our Tubulis assets? Absolutely. I think, again, back to the previous discussion we had, I do not want to repeat myself, we do not have to own everything. We can partner where it is strategically important and capable for us, then certainly we will think about bringing them into our pipeline and our portfolio.
Now, as you mentioned, you do not have an LOE until past 2035. Your team is consistently, if there is one adjective, it is the term disciplined. There have been deals that your teams looked at, felt the price did not really make sense. As we get towards the end of the decade, and you now have foundational assets, right, how does your BD strategy evolve? Does the risk tolerance go up? Does your willingness to, let us say, pay for revenue diversification for a fair price, right? If you talk to Lilly, they will say, we want to be an investor. We want to take a risk. We do not want to get a dollar to give a dollar. That does not make sense to us. But sometimes we will see with stock price, that is what investors want the most. They want revenue diversification and certainty.
As we get more towards the end of the decade, do you feel like there could be a shift where you start looking at more pragmatic commercial stage acquisitions?
Yeah, I'm happy to start. Look, I think there's already been a shift. Maybe the most important thing is we've completely rebuilt the pipeline in the company. One of the things that's underappreciated today, and you're seeing this in inflammation, we talked about it, is that we've tripled the size of our research. We've right-sized our internal research investment. When Dan and I joined, we were under-investing in R&D as a percentage of revenue every year. We have a much stronger pipeline. To give you an example, we now have 10, 11, 12 compounds moving from research into our clinical development that are internally generated every year. When I joined the company 10 years ago, that was two, three, or four molecules at most a year. We've completely transformed our internal research, which is going to drive long-term growth and diversification.
The second thing is we have a very strong mid-stage pipeline. We've done four deals this year to cement and solidify the mid-stage pipeline. You talked about Tubulis. We talked a little bit about Ouro or gamgertamig, the B cell depleter, the IL-23. We already had a nice set of mid-stage assets, but we wanted to add to that. That's going to all add growth. The final piece, and I'll get to your question on M&A, is we're in the middle of. We have a number of launches underway. We have three more coming in the near term, a total of eight launches. I think five underway and three more coming in the next 18 months, all of which are already starting to drive growth in the business across HIV treatment, HIV prevention, where you see really strong growth. TRODELVY's growing beautifully in first-line triple-negative breast cancer.
In HR-positive breast cancer, LIVDELZI and PBC is growing beautifully. You're already seeing that growth. All of our efforts to diversify the business, both within HIV and outside of HIV, are already bearing fruit. To your point, we have 10 years to add to that. This year, we'll generate $13 billion, roughly, of free cash flow. We have the ability to add additional assets to our portfolio, and we will do that over time. But in terms of the shift, the need to do large late-stage deals today is completely different than the need that Dan and I inherited 8- 10 years ago, where we had to rebuild the pipeline and invest substantially in the business. We will keep adding assets.
We are looking for assets that are late stage, that can even further drive kind of our revenue growth and diversification, but we will be very disciplined in doing that, and we have a long time, so s teady, consistent cadence of deals. We have a lot of flexibility, but the bar is definitely higher today than it was five years ago, and certainly than 10 years ago, as we had to kind of effectively rebuild the company.
Right. It's interesting, Andy, when we've talked about this in the past, I remember last year in London, you're like, look, sometimes our problem is not these mid-cap CEOs, it's these pharmas. I remember sensing that there was a BD environment where there was more, let's say, of a frenzy and a negotiation period, and that became difficult when you thought about value. I can certainly understand that. Are we in a different environment today where you feel like there might be more pragmatism we're seeing on the biotech CEO side, but also that from the pharma side, the large-cap biotech side, they're also being more disciplined in terms of what types of assets they're looking to get into their portfolios?
Yeah, I think what Akash is highlighting, there are a number of deals over the last two years that many of them we actually started the process or participated in the process, but people were willing to get to levels that we didn't see the same in terms of value. Frankly, that's always the case with every M&A deal. Even the IL-23 that we just acquired, there were at least two other very large companies competing in that process. I would say that the important point here is our need is just very different than many of our peers. Many of our peers are facing these very large patent cliffs, so their need is just by definition going to be different, and I think we saw a little bit of that last year and the year before.
But as long as we continue to be disciplined, continue to invest in internal, in our pipeline, and add selectively to it, I think we're going to be in a really good spot.
Understood. Now, maybe going into HIV, there's another dynamic where maybe people see it, but you have to really, I actually think people are missing this. When we think about BIKTARVY, right, going from multiple pills to single pill and helping with on the tox side, I felt like there was maybe initially investor skepticism, man, is that really going to be a new product opportunity? I think with long-acting, in terms of paradigm shift of how HIV is treated, adherence, from a health economic perspective, this to me is one of the biggest shifts we're going to see, and I don't think people appreciate that.
What does, when we think about PrEP and then also when we think about antiviral treatment, the adoption of long-acting regimens, how does that change the business for you? And then, how does that really change how HIV is treated from a health economic perspective for the U.S. government and worldwide?
Yeah. I tend to agree with your thesis. I think there's no doubt that even when you do market research today, majority of people would love to move to a long-acting regimen. What I believe is that as we get deeper into that, even more people will want to do that. But at the end of the day, in treatment, I really do think the market will move to long-acting, and it's going to start as early as this next year with our first once-weekly oral pill. But beyond that, we have investment in treatment on monthly, on every six-month injectables. Those are in the clinic now, so the bNAbs and lenacapavir are in the clinic, and we've got an INSTI GS-3242 in the clinic right now on an every four-month basis, and we're doing the PK right now for the six-month basis.
I do think that the market will move to that. The other thing to remember is that in the United States alone, there's around 40% of people that are not virologically suppressed. In other words, they have the virus, and they're not virologically suppressed. At least 20% of that is because taking a daily oral regimen just doesn't fit into their lives for a variety of reasons. So, I think it's not just a zero-sum game when you think about the current treatment market with long-actings. It's also the ability to get to people that are not served well by daily orals. We have up to five additional long-acting treatment launches between now and the BIKTARVY patent expiry in 2036. Exactly what that mix looks like, some people might prefer long-acting orals, some long-acting injectables, I don't know.
But the point is, I think there's a tremendous opportunity to have both a patient benefit and the economic benefit on the treatment side. On prevention, there's no doubt that people that don't have a disease really don't want to take a daily pill and be reminded of their disease all the time. Obviously, YEZTUGO's off to a great start every six months. We expect to have the potential to have a once-yearly shot in 2028 of YEZTUGO on the injectable side, and then we are launching a once-weekly oral version of YEZTUGO in the first quarter of next year. All this to suggest, look, the PrEP market today is growing at about 14% in the United States, and that's a highly under-penetrated market. Only about one out of four people, as defined by CDC today, are on a PrEP regimen in the United States.
There's tremendous opportunity, I think, over time to get more people under care, to help people not get this disease, and certainly the economic benefits over time are important.
To that point, you alluded to the oral YEZTUGO option, which again, I think I'll take that. I want more surprise phase III-ready programs. That can happen any day. I'll take it. We've seen a really strong launch out of the gate for YEZTUGO. Then, there was also a buy and build element to it that you had to kind of rewire the system in a way that may not actually be the case when you think about an oral product. When you think about the trajectory we've seen out of the gate with YEZTUGO, and we think about now an oral weekly option, could we see a faster launch, than what we've seen with YEZTUGO? Do you feel like there's a bolus of patients who are really waiting for a therapy like this?
I don't know about the bolus, but definitely a faster launch in terms of access and reimbursement. In other words, today, YEZTUGO is approved by both pharmacy and medical benefits. The oral version will be a pharmacy benefit. For about 70% of the folks, there'll be kind of an immediate access to the weekly oral treatment, and I'm sure that'll grow over time. We won't have the same initiation challenges with the weekly oral that we had with the twice-a-year injectable. I think there's a tremendous opportunity to get people that are either on branded or, importantly, generic PrEP options today to a more convenient option that they can live with on a once-weekly basis. That's just the current market. The expansion of the market, I think, is also highly likely.
The point is, I think, yes, I think there are some people that are waiting, but it'll bring more people into care, and really convert the current oral market to a once-weekly oral market over time.
Understood. I know we are out of time, but I really did enjoy the discussion. Thanks so much.
Thank you very much.
Thank you.